| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Neoplasms | 13 | 2024 | 297 | 4.330 |
Why?
|
| Ovarian Neoplasms | 17 | 2023 | 766 | 3.270 |
Why?
|
| Endometrial Neoplasms | 8 | 2022 | 208 | 2.810 |
Why?
|
| Genital Neoplasms, Female | 4 | 2023 | 108 | 2.270 |
Why?
|
| Carcinoma, Endometrioid | 5 | 2022 | 49 | 2.170 |
Why?
|
| Uterine Cervical Dysplasia | 3 | 2023 | 33 | 1.810 |
Why?
|
| Uterine Neoplasms | 6 | 2024 | 248 | 1.520 |
Why?
|
| Papillomavirus Infections | 3 | 2023 | 263 | 1.360 |
Why?
|
| Cytodiagnosis | 5 | 2023 | 46 | 1.230 |
Why?
|
| Thyroid Neoplasms | 5 | 2024 | 425 | 1.160 |
Why?
|
| Sex Cord-Gonadal Stromal Tumors | 3 | 2020 | 19 | 1.150 |
Why?
|
| Biomarkers, Tumor | 7 | 2020 | 1535 | 1.080 |
Why?
|
| Ovary | 5 | 2022 | 262 | 1.060 |
Why?
|
| Female | 59 | 2024 | 46328 | 1.030 |
Why?
|
| Immunohistochemistry | 13 | 2021 | 1793 | 1.020 |
Why?
|
| Placenta Diseases | 1 | 2024 | 13 | 0.920 |
Why?
|
| Hemangioma | 1 | 2024 | 64 | 0.900 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 2 | 2020 | 24 | 0.860 |
Why?
|
| MutL Protein Homolog 1 | 2 | 2020 | 35 | 0.860 |
Why?
|
| Neoplasms, Glandular and Epithelial | 4 | 2017 | 75 | 0.810 |
Why?
|
| Adenocarcinoma | 4 | 2018 | 1185 | 0.810 |
Why?
|
| Teratoma | 2 | 2023 | 52 | 0.800 |
Why?
|
| Carcinoma | 2 | 2016 | 438 | 0.790 |
Why?
|
| Humans | 69 | 2024 | 89500 | 0.780 |
Why?
|
| Cystadenoma, Papillary | 1 | 2021 | 9 | 0.760 |
Why?
|
| Ascitic Fluid | 2 | 2022 | 38 | 0.760 |
Why?
|
| Cervix Uteri | 5 | 2024 | 71 | 0.740 |
Why?
|
| Biopsy, Fine-Needle | 5 | 2024 | 107 | 0.740 |
Why?
|
| Gynecology | 1 | 2023 | 130 | 0.740 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 2023 | 48 | 0.730 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2021 | 333 | 0.720 |
Why?
|
| Trophoblastic Neoplasms | 1 | 2020 | 5 | 0.700 |
Why?
|
| Middle Aged | 28 | 2024 | 25971 | 0.700 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2024 | 1097 | 0.690 |
Why?
|
| Epithelioid Cells | 1 | 2020 | 13 | 0.690 |
Why?
|
| Mucolipidoses | 1 | 2019 | 3 | 0.670 |
Why?
|
| Transferases (Other Substituted Phosphate Groups) | 1 | 2019 | 11 | 0.670 |
Why?
|
| Papillomaviridae | 2 | 2023 | 155 | 0.660 |
Why?
|
| Lymph Nodes | 1 | 2022 | 550 | 0.620 |
Why?
|
| Leiomyosarcoma | 3 | 2024 | 45 | 0.620 |
Why?
|
| Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 1 | 2018 | 8 | 0.610 |
Why?
|
| Hypertension | 1 | 2024 | 745 | 0.600 |
Why?
|
| Receptors, Glucocorticoid | 5 | 2024 | 128 | 0.600 |
Why?
|
| DNA Repair Enzymes | 1 | 2018 | 55 | 0.600 |
Why?
|
| Urologic Neoplasms | 1 | 2019 | 74 | 0.600 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2017 | 8 | 0.580 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2019 | 151 | 0.570 |
Why?
|
| Adult | 24 | 2024 | 26659 | 0.560 |
Why?
|
| Gene Expression Profiling | 4 | 2021 | 1445 | 0.550 |
Why?
|
| Placenta | 3 | 2024 | 181 | 0.540 |
Why?
|
| Neoplasm Staging | 8 | 2024 | 1997 | 0.530 |
Why?
|
| Mucins | 1 | 2016 | 39 | 0.520 |
Why?
|
| Papanicolaou Test | 2 | 2021 | 39 | 0.520 |
Why?
|
| Sarcoma, Alveolar Soft Part | 1 | 2015 | 3 | 0.510 |
Why?
|
| SOXE Transcription Factors | 1 | 2015 | 5 | 0.500 |
Why?
|
| Nestin | 1 | 2015 | 18 | 0.500 |
Why?
|
| Inhibins | 1 | 2015 | 37 | 0.500 |
Why?
|
| Specimen Handling | 2 | 2022 | 102 | 0.500 |
Why?
|
| DNA-Binding Proteins | 3 | 2021 | 1242 | 0.500 |
Why?
|
| S100 Proteins | 1 | 2015 | 52 | 0.490 |
Why?
|
| Aged | 21 | 2024 | 19124 | 0.490 |
Why?
|
| Fibroma, Ossifying | 1 | 2014 | 6 | 0.470 |
Why?
|
| Prognosis | 12 | 2024 | 3777 | 0.450 |
Why?
|
| Atypical Squamous Cells of the Cervix | 1 | 2013 | 2 | 0.450 |
Why?
|
| Retrospective Studies | 12 | 2024 | 9097 | 0.450 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2014 | 55 | 0.440 |
Why?
|
| Aged, 80 and over | 10 | 2024 | 6761 | 0.440 |
Why?
|
| Pregnancy | 5 | 2024 | 3035 | 0.430 |
Why?
|
| Osteosarcoma | 1 | 2014 | 161 | 0.430 |
Why?
|
| Neurofibromatosis 1 | 1 | 2012 | 39 | 0.390 |
Why?
|
| Bone Neoplasms | 1 | 2014 | 320 | 0.380 |
Why?
|
| Thyroid Nodule | 3 | 2024 | 59 | 0.370 |
Why?
|
| Endometrial Hyperplasia | 2 | 2022 | 11 | 0.370 |
Why?
|
| RNA-Binding Proteins | 1 | 2013 | 277 | 0.360 |
Why?
|
| Pathologists | 2 | 2024 | 27 | 0.360 |
Why?
|
| Lymphatic Metastasis | 5 | 2024 | 496 | 0.360 |
Why?
|
| Embolism, Fat | 1 | 2010 | 2 | 0.350 |
Why?
|
| Neoplasm Metastasis | 6 | 2020 | 1064 | 0.350 |
Why?
|
| Peritoneal Lavage | 2 | 2022 | 12 | 0.350 |
Why?
|
| Diagnosis, Differential | 4 | 2021 | 1605 | 0.350 |
Why?
|
| Fractures, Compression | 1 | 2010 | 17 | 0.350 |
Why?
|
| Neoplasm Invasiveness | 5 | 2024 | 571 | 0.340 |
Why?
|
| Thoracic Vertebrae | 1 | 2010 | 51 | 0.340 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 2 | 2024 | 105 | 0.330 |
Why?
|
| Young Adult | 7 | 2020 | 6354 | 0.330 |
Why?
|
| Peritoneal Neoplasms | 2 | 2023 | 181 | 0.310 |
Why?
|
| Cancer-Associated Fibroblasts | 2 | 2019 | 37 | 0.310 |
Why?
|
| Cell Line, Tumor | 11 | 2024 | 2578 | 0.310 |
Why?
|
| Hysterectomy | 3 | 2019 | 152 | 0.310 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2024 | 1277 | 0.310 |
Why?
|
| Neoadjuvant Therapy | 2 | 2021 | 373 | 0.300 |
Why?
|
| Proteomics | 3 | 2020 | 231 | 0.300 |
Why?
|
| Brain | 1 | 2018 | 2292 | 0.290 |
Why?
|
| Cystadenocarcinoma, Serous | 2 | 2018 | 49 | 0.290 |
Why?
|
| Antibodies, Monoclonal | 1 | 2013 | 1394 | 0.280 |
Why?
|
| Fallopian Tubes | 3 | 2022 | 42 | 0.280 |
Why?
|
| Early Detection of Cancer | 2 | 2023 | 418 | 0.280 |
Why?
|
| Transcription Factors | 3 | 2024 | 1658 | 0.280 |
Why?
|
| Curettage | 2 | 2018 | 14 | 0.280 |
Why?
|
| Biopsy | 4 | 2019 | 1183 | 0.270 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2021 | 487 | 0.270 |
Why?
|
| Phenylthiohydantoin | 2 | 2024 | 46 | 0.260 |
Why?
|
| Infant, Newborn | 2 | 2024 | 2487 | 0.250 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2023 | 105 | 0.250 |
Why?
|
| Sequence Analysis, DNA | 2 | 2021 | 868 | 0.250 |
Why?
|
| Benzamides | 2 | 2024 | 234 | 0.250 |
Why?
|
| Thyroid Gland | 2 | 2024 | 280 | 0.240 |
Why?
|
| Epithelial Cells | 3 | 2018 | 688 | 0.230 |
Why?
|
| Papilloma | 1 | 2023 | 22 | 0.220 |
Why?
|
| Lung Neoplasms | 2 | 2014 | 2362 | 0.220 |
Why?
|
| Lymph Node Excision | 2 | 2022 | 219 | 0.220 |
Why?
|
| Lung | 1 | 2010 | 1270 | 0.220 |
Why?
|
| Postmenopause | 2 | 2022 | 102 | 0.220 |
Why?
|
| Ki-67 Antigen | 1 | 2023 | 67 | 0.210 |
Why?
|
| Rare Diseases | 2 | 2020 | 69 | 0.210 |
Why?
|
| Vaginal Smears | 1 | 2023 | 71 | 0.210 |
Why?
|
| DNA Mismatch Repair | 2 | 2019 | 58 | 0.190 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2021 | 19 | 0.190 |
Why?
|
| Submandibular Gland Neoplasms | 1 | 2021 | 7 | 0.190 |
Why?
|
| Quality Assurance, Health Care | 1 | 2023 | 224 | 0.190 |
Why?
|
| Submandibular Gland | 1 | 2021 | 17 | 0.190 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2021 | 25 | 0.190 |
Why?
|
| Parotid Neoplasms | 1 | 2021 | 18 | 0.190 |
Why?
|
| Parotid Gland | 1 | 2021 | 32 | 0.180 |
Why?
|
| Endometrial Stromal Tumors | 1 | 2020 | 5 | 0.180 |
Why?
|
| Nuclear Receptor Coactivator 2 | 1 | 2020 | 16 | 0.180 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 327 | 0.180 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2021 | 61 | 0.180 |
Why?
|
| Microscopy, Electron | 1 | 2021 | 511 | 0.180 |
Why?
|
| Glioma | 1 | 2023 | 294 | 0.180 |
Why?
|
| Predictive Value of Tests | 4 | 2021 | 1727 | 0.180 |
Why?
|
| Receptors, Estrogen | 2 | 2019 | 394 | 0.180 |
Why?
|
| Chromatin | 2 | 2022 | 401 | 0.180 |
Why?
|
| Phenotype | 4 | 2019 | 2447 | 0.180 |
Why?
|
| Point Mutation | 1 | 2021 | 245 | 0.180 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2020 | 25 | 0.170 |
Why?
|
| Gonadal Dysgenesis, 46,XY | 1 | 2019 | 4 | 0.170 |
Why?
|
| Puberty, Delayed | 1 | 2019 | 19 | 0.170 |
Why?
|
| Amenorrhea | 1 | 2019 | 28 | 0.170 |
Why?
|
| Mullerian Ducts | 1 | 2019 | 18 | 0.170 |
Why?
|
| Glycolysis | 2 | 2018 | 135 | 0.170 |
Why?
|
| Adnexa Uteri | 1 | 2019 | 11 | 0.170 |
Why?
|
| Cohort Studies | 3 | 2021 | 2876 | 0.170 |
Why?
|
| Sensitivity and Specificity | 2 | 2014 | 2015 | 0.170 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2020 | 47 | 0.170 |
Why?
|
| Adnexal Diseases | 1 | 2019 | 16 | 0.170 |
Why?
|
| Pregnancy, Twin | 1 | 2019 | 8 | 0.170 |
Why?
|
| Nicotinamide N-Methyltransferase | 1 | 2019 | 6 | 0.170 |
Why?
|
| Flow Cytometry | 2 | 2019 | 689 | 0.170 |
Why?
|
| Genotyping Techniques | 1 | 2020 | 68 | 0.170 |
Why?
|
| Cell Proliferation | 6 | 2024 | 1668 | 0.170 |
Why?
|
| Twins | 1 | 2019 | 65 | 0.160 |
Why?
|
| Pelvic Exenteration | 1 | 2019 | 5 | 0.160 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2019 | 72 | 0.160 |
Why?
|
| Microsatellite Instability | 1 | 2019 | 53 | 0.160 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2020 | 603 | 0.160 |
Why?
|
| Lymphadenopathy | 1 | 2019 | 20 | 0.160 |
Why?
|
| Mesonephroma | 1 | 2018 | 5 | 0.160 |
Why?
|
| Adipocytes | 1 | 2020 | 163 | 0.160 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2019 | 80 | 0.160 |
Why?
|
| Cervical Vertebrae | 1 | 2019 | 84 | 0.160 |
Why?
|
| Leiomyoma | 1 | 2022 | 203 | 0.150 |
Why?
|
| Glycogen | 1 | 2018 | 59 | 0.150 |
Why?
|
| Neoplasm Grading | 4 | 2023 | 372 | 0.150 |
Why?
|
| Triage | 1 | 2019 | 113 | 0.150 |
Why?
|
| Genomics | 2 | 2021 | 774 | 0.150 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2018 | 33 | 0.150 |
Why?
|
| Fetus | 1 | 2019 | 232 | 0.150 |
Why?
|
| DNA | 1 | 2024 | 1309 | 0.150 |
Why?
|
| Cystectomy | 1 | 2019 | 106 | 0.150 |
Why?
|
| Mammary Glands, Animal | 1 | 2018 | 80 | 0.150 |
Why?
|
| Salpingo-oophorectomy | 1 | 2017 | 3 | 0.150 |
Why?
|
| Adenoma | 1 | 2019 | 247 | 0.140 |
Why?
|
| MicroRNAs | 1 | 2022 | 555 | 0.140 |
Why?
|
| Metformin | 1 | 2019 | 124 | 0.140 |
Why?
|
| Small Molecule Libraries | 1 | 2017 | 65 | 0.140 |
Why?
|
| Mice, Nude | 4 | 2020 | 816 | 0.140 |
Why?
|
| Adenocarcinoma in Situ | 1 | 2016 | 4 | 0.140 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2016 | 36 | 0.140 |
Why?
|
| Psychotic Disorders | 1 | 2018 | 194 | 0.130 |
Why?
|
| Kidney Neoplasms | 1 | 2021 | 523 | 0.130 |
Why?
|
| Transcriptome | 2 | 2018 | 652 | 0.130 |
Why?
|
| Mutation | 4 | 2021 | 4158 | 0.130 |
Why?
|
| Male | 9 | 2024 | 42438 | 0.130 |
Why?
|
| BRCA1 Protein | 1 | 2017 | 204 | 0.130 |
Why?
|
| Mitosis | 1 | 2016 | 152 | 0.130 |
Why?
|
| Seizures | 1 | 2018 | 307 | 0.130 |
Why?
|
| Hematologic Neoplasms | 1 | 2019 | 343 | 0.120 |
Why?
|
| Neoplasms | 3 | 2022 | 3052 | 0.120 |
Why?
|
| Risk Assessment | 3 | 2022 | 2303 | 0.120 |
Why?
|
| Stress, Psychological | 1 | 2018 | 321 | 0.120 |
Why?
|
| Breast Neoplasms | 2 | 2019 | 3018 | 0.120 |
Why?
|
| Tarsal Bones | 1 | 2014 | 9 | 0.120 |
Why?
|
| Immunotherapy | 1 | 2020 | 686 | 0.120 |
Why?
|
| Fas Ligand Protein | 1 | 2014 | 49 | 0.120 |
Why?
|
| Genotype | 1 | 2019 | 1852 | 0.120 |
Why?
|
| Ultrasonography, Doppler | 1 | 2014 | 85 | 0.120 |
Why?
|
| Pathology | 1 | 2014 | 32 | 0.110 |
Why?
|
| Mice | 7 | 2024 | 11812 | 0.110 |
Why?
|
| Minichromosome Maintenance Proteins | 1 | 2013 | 3 | 0.110 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2013 | 21 | 0.110 |
Why?
|
| Biopsy, Needle | 1 | 2014 | 231 | 0.110 |
Why?
|
| Antineoplastic Agents | 3 | 2020 | 2323 | 0.110 |
Why?
|
| Carcinoma, Papillary | 1 | 2014 | 156 | 0.110 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2019 | 482 | 0.110 |
Why?
|
| Staining and Labeling | 1 | 2013 | 168 | 0.110 |
Why?
|
| Animals | 10 | 2024 | 27453 | 0.110 |
Why?
|
| Adolescent | 3 | 2020 | 9289 | 0.100 |
Why?
|
| Time Factors | 2 | 2020 | 5330 | 0.100 |
Why?
|
| Fatal Outcome | 2 | 2010 | 296 | 0.100 |
Why?
|
| Apoptosis | 2 | 2016 | 1716 | 0.100 |
Why?
|
| Endothelium, Vascular | 1 | 2014 | 432 | 0.100 |
Why?
|
| Sarcoma, Clear Cell | 1 | 2011 | 3 | 0.100 |
Why?
|
| Cell Survival | 3 | 2020 | 982 | 0.100 |
Why?
|
| Perivascular Epithelioid Cell Neoplasms | 1 | 2011 | 9 | 0.100 |
Why?
|
| Immune Tolerance | 1 | 2014 | 339 | 0.100 |
Why?
|
| Antigens, Neoplasm | 1 | 2013 | 334 | 0.090 |
Why?
|
| Constriction, Pathologic | 1 | 2012 | 218 | 0.090 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2014 | 307 | 0.090 |
Why?
|
| Interferon Regulatory Factors | 1 | 2011 | 69 | 0.090 |
Why?
|
| Treatment Outcome | 3 | 2021 | 8200 | 0.090 |
Why?
|
| Nitriles | 2 | 2024 | 156 | 0.090 |
Why?
|
| Receptors, Androgen | 2 | 2024 | 119 | 0.090 |
Why?
|
| Reproducibility of Results | 3 | 2023 | 2762 | 0.090 |
Why?
|
| Disease Progression | 3 | 2019 | 1462 | 0.080 |
Why?
|
| Epigenesis, Genetic | 2 | 2024 | 517 | 0.080 |
Why?
|
| Gene Expression | 1 | 2013 | 1309 | 0.080 |
Why?
|
| Coculture Techniques | 2 | 2020 | 175 | 0.080 |
Why?
|
| Disease-Free Survival | 2 | 2024 | 1172 | 0.080 |
Why?
|
| Jejunal Neoplasms | 1 | 2008 | 9 | 0.080 |
Why?
|
| Radiography | 1 | 2010 | 806 | 0.070 |
Why?
|
| Mass Spectrometry | 2 | 2020 | 194 | 0.070 |
Why?
|
| Intestinal Obstruction | 1 | 2008 | 89 | 0.070 |
Why?
|
| Melanoma | 1 | 2011 | 467 | 0.070 |
Why?
|
| Tumor Microenvironment | 2 | 2023 | 470 | 0.070 |
Why?
|
| Observer Variation | 2 | 2021 | 612 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2019 | 477 | 0.070 |
Why?
|
| United States | 2 | 2016 | 7033 | 0.070 |
Why?
|
| Signal Transduction | 3 | 2024 | 3392 | 0.060 |
Why?
|
| Cell Movement | 2 | 2019 | 785 | 0.060 |
Why?
|
| DNA Methylation | 2 | 2020 | 660 | 0.060 |
Why?
|
| Azepines | 1 | 2024 | 25 | 0.060 |
Why?
|
| Asia | 1 | 2024 | 100 | 0.060 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2024 | 66 | 0.060 |
Why?
|
| Benzodiazepines | 1 | 2024 | 68 | 0.060 |
Why?
|
| North America | 1 | 2024 | 184 | 0.060 |
Why?
|
| Triazoles | 1 | 2024 | 104 | 0.060 |
Why?
|
| Europe | 1 | 2024 | 322 | 0.060 |
Why?
|
| Transcription, Genetic | 2 | 2019 | 1158 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 3658 | 0.050 |
Why?
|
| Ascites | 1 | 2023 | 56 | 0.050 |
Why?
|
| Tissue Fixation | 1 | 2022 | 40 | 0.050 |
Why?
|
| Paraffin Embedding | 1 | 2022 | 78 | 0.050 |
Why?
|
| Formaldehyde | 1 | 2022 | 52 | 0.050 |
Why?
|
| Cell Cycle Proteins | 1 | 2024 | 398 | 0.050 |
Why?
|
| Glucocorticoids | 1 | 2024 | 357 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 2375 | 0.050 |
Why?
|
| Necrosis | 1 | 2022 | 210 | 0.050 |
Why?
|
| SMARCB1 Protein | 1 | 2021 | 13 | 0.050 |
Why?
|
| Azure Stains | 1 | 2021 | 6 | 0.050 |
Why?
|
| Methylene Blue | 1 | 2021 | 18 | 0.050 |
Why?
|
| Xanthenes | 1 | 2021 | 23 | 0.050 |
Why?
|
| Oncogene Fusion | 1 | 2020 | 10 | 0.050 |
Why?
|
| Single-Cell Analysis | 1 | 2022 | 155 | 0.050 |
Why?
|
| Tissue Array Analysis | 1 | 2021 | 126 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2023 | 412 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2021 | 84 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2022 | 213 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2019 | 2354 | 0.040 |
Why?
|
| Protein Array Analysis | 1 | 2020 | 52 | 0.040 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2020 | 24 | 0.040 |
Why?
|
| Biphenyl Compounds | 1 | 2020 | 59 | 0.040 |
Why?
|
| Heterografts | 1 | 2020 | 102 | 0.040 |
Why?
|
| Omentum | 1 | 2020 | 74 | 0.040 |
Why?
|
| Hypogonadism | 1 | 2019 | 40 | 0.040 |
Why?
|
| Metabolomics | 1 | 2020 | 76 | 0.040 |
Why?
|
| S-Adenosylhomocysteine | 1 | 2019 | 9 | 0.040 |
Why?
|
| S-Adenosylmethionine | 1 | 2019 | 17 | 0.040 |
Why?
|
| Sentinel Lymph Node | 1 | 2019 | 17 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2020 | 247 | 0.040 |
Why?
|
| Niacinamide | 1 | 2019 | 97 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2019 | 152 | 0.040 |
Why?
|
| Incidence | 1 | 2023 | 1598 | 0.040 |
Why?
|
| Proteins | 1 | 2024 | 786 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2020 | 149 | 0.040 |
Why?
|
| Carboplatin | 1 | 2020 | 310 | 0.040 |
Why?
|
| 5-Methylcytosine | 1 | 2020 | 117 | 0.040 |
Why?
|
| Gene Dosage | 1 | 2019 | 210 | 0.040 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2019 | 79 | 0.040 |
Why?
|
| Lipid Metabolism | 1 | 2020 | 201 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2020 | 305 | 0.040 |
Why?
|
| Sphingosine | 1 | 2019 | 74 | 0.040 |
Why?
|
| Lysophospholipids | 1 | 2019 | 66 | 0.040 |
Why?
|
| RNA | 1 | 2022 | 581 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2020 | 520 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2019 | 294 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2024 | 2021 | 0.040 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2018 | 57 | 0.040 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2019 | 156 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2018 | 197 | 0.040 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2019 | 171 | 0.040 |
Why?
|
| Cell Cycle | 1 | 2019 | 508 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2022 | 1860 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2020 | 725 | 0.040 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2017 | 33 | 0.040 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2019 | 284 | 0.040 |
Why?
|
| Histones | 1 | 2019 | 332 | 0.030 |
Why?
|
| Chemoprevention | 1 | 2017 | 92 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 279 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2016 | 76 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2020 | 538 | 0.030 |
Why?
|
| Ontario | 1 | 2016 | 51 | 0.030 |
Why?
|
| Datasets as Topic | 1 | 2016 | 75 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2021 | 726 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2016 | 83 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2018 | 557 | 0.030 |
Why?
|
| Hypoglycemic Agents | 1 | 2019 | 351 | 0.030 |
Why?
|
| Aspirin | 1 | 2017 | 160 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2019 | 539 | 0.030 |
Why?
|
| Algorithms | 1 | 2024 | 1894 | 0.030 |
Why?
|
| Protein Binding | 1 | 2019 | 1490 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2018 | 1237 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2016 | 1048 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2018 | 961 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 2016 | 221 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2018 | 1496 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1076 | 0.030 |
Why?
|
| Jurkat Cells | 1 | 2014 | 77 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2014 | 95 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2019 | 2884 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2014 | 169 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 948 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2014 | 171 | 0.030 |
Why?
|
| Survival Rate | 1 | 2017 | 1886 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2019 | 1353 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2014 | 793 | 0.030 |
Why?
|
| Antibodies | 1 | 2014 | 353 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2014 | 405 | 0.030 |
Why?
|
| Rats | 1 | 2018 | 4040 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2014 | 1090 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2018 | 1529 | 0.020 |
Why?
|
| Child | 1 | 2023 | 7210 | 0.020 |
Why?
|
| Phylogeny | 1 | 2016 | 1191 | 0.020 |
Why?
|
| Risk Factors | 1 | 2019 | 5518 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2014 | 3228 | 0.020 |
Why?
|